{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T07:17:27Z","timestamp":1717831047256},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.ejca.2013.09.016","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T13:00:40Z","timestamp":1382101240000},"page":"234-246","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["DNA vaccination against membrane-bound Kit ligand: A new approach to inhibiting tumour growth and angiogenesis"],"prefix":"10.1016","volume":"50","author":[{"given":"Cristina","family":"Olgasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Dentelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Iavello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Togliatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Toto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcella","family":"Liberatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Barutello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Musiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Felice","family":"Brizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.09.016_b0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccr.2005.02.013","article-title":"Smoldering and polarized inflammation in the initiation and promotion of malignant disease","volume":"3","author":"Balkwill","year":"2005","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ejca.2013.09.016_b0010","first-page":"523","article-title":"Cheng G expression of stem cell factor and c-kit mRNA in cultured endothelial cells, monocytes and cloned human bone marrow stromal cells (CFU-RF)","volume":"20","author":"Aye","year":"1992","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.016_b0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/01.ATV.0000257148.01384.7d","article-title":"Stem cell factor attenuates vascular smooth muscle apoptosis and increases intimal hyperplasia after vascular injury","volume":"27","author":"Wang","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.016_b0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1091\/mbc.3.3.349","article-title":"Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2","volume":"3","author":"Huang","year":"1992","journal-title":"Mol Biol Cell"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.016_b0025","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.V85.3.641.bloodjournal853641","article-title":"Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form","volume":"85","author":"Miyazawa","year":"1995","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejca.2013.09.016_b0030","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2006-06-029603","article-title":"C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium","volume":"109","author":"Dentelli","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2013.09.016_b0035","first-page":"365","article-title":"The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow","volume":"26","author":"Slanicka Krieger","year":"1998","journal-title":"Exp Hematol"},{"issue":"9","key":"10.1016\/j.ejca.2013.09.016_b0040","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1096\/fj.02-0557fje","article-title":"Altered angiogenesis and survival in human tumor-derived endothelial cells","volume":"17","author":"Bussolati","year":"2003","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.ejca.2013.09.016_b0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2007-04-086835","article-title":"Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function","volume":"111","author":"Pan","year":"2008","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.ejca.2013.09.016_b0050","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1038\/onc.2011.204","article-title":"IL-3 is a novel target to interfere with tumor vasculature","volume":"30","author":"Dentelli","year":"2011","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.ejca.2013.09.016_b0055","first-page":"4343","article-title":"Abrogation of c-kit\/Steel factor-dependent tumorigenesis by kinase defective mutants of the c-kit receptor: c-kit kinase defective mutants as candidate tools for cancer gene therapy","volume":"56","author":"Li","year":"1996","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2013.09.016_b0060","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/onc.2011.289","article-title":"C-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer","volume":"31","author":"Regan","year":"2012","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ejca.2013.09.016_b0065","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrclinonc.2009.52","article-title":"Anticancer strategies involving the vasculature","volume":"6","author":"Heath","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"53","key":"10.1016\/j.ejca.2013.09.016_b0070","first-page":"355","article-title":"Development of anti-cancer drugs","volume":"10","author":"Arrondeau","year":"2012","journal-title":"Discov Med"},{"issue":"2","key":"10.1016\/j.ejca.2013.09.016_b0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.016_b0080","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrc1815","article-title":"Vaccines for tumour prevention","volume":"6","author":"Lollini","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2013.09.016_b0085","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrc2208","article-title":"Are oncoantigens suitable targets for anti-tumour therapy?","volume":"7","author":"Cavallo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2013.09.016_b0090","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nrc2250","article-title":"Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy","volume":"7","author":"Colombo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2013.09.016_b0095","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm1202-794","article-title":"A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth","volume":"8","author":"Niethammer","year":"2002","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.ejca.2013.09.016_b0100","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1073\/pnas.0603110103","article-title":"A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth","volume":"103","author":"Holmgren","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"30","key":"10.1016\/j.ejca.2013.09.016_b0105","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1038\/onc.2010.176","article-title":"Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma","volume":"29","author":"Haller","year":"2010","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ejca.2013.09.016_b0110","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1172\/JCI42405","article-title":"Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma","volume":"121","author":"Cascone","year":"2011","journal-title":"J Clin Invest"},{"issue":"50","key":"10.1016\/j.ejca.2013.09.016_b0115","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1038\/onc.2010.384","article-title":"Inhibition of \u03b21 integrin and IL-3R\u03b2 common subunit interaction hinders tumour angiogenesis","volume":"29","author":"Uberti","year":"2010","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ejca.2013.09.016_b0120","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/ATVBAHA.110.206201","article-title":"MicroRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression","volume":"30","author":"Dentelli","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.ejca.2013.09.016_b0125","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1007\/s00125-011-2125-5","article-title":"MIR221\/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage","volume":"54","author":"Togliatto","year":"2011","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ejca.2013.09.016_b0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0167-5699(97)80012-6","article-title":"Cytokines, tumour-cell death and immunogenicity: a question of choice","volume":"18","author":"Musiani","year":"1997","journal-title":"Immunol Today"},{"issue":"6","key":"10.1016\/j.ejca.2013.09.016_b0135","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.4049\/jimmunol.164.6.3200","article-title":"Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes","volume":"164","author":"Giovarelli","year":"2000","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.ejca.2013.09.016_b0140","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2008-03-147033","article-title":"SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment","volume":"112","author":"Huang","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2013.09.016_b0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gde.2010.10.008","article-title":"Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications","volume":"21","author":"De Bock","year":"2011","journal-title":"Curr Opin Genet Dev"},{"issue":"10","key":"10.1016\/j.ejca.2013.09.016_b0150","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1096\/fj.04-3099fje","article-title":"STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells","volume":"19","author":"Jung","year":"2005","journal-title":"FASEB J"},{"issue":"10","key":"10.1016\/j.ejca.2013.09.016_b0155","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2011-01-331694","article-title":"Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression","volume":"118","author":"Franco","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.016_b0160","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2002-01-0177","article-title":"Necessity of tyrosine 719 and phosphatidylinositol 3\u2032-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation","volume":"101","author":"Hashimoto","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.016_b0165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00262-010-0968-0","article-title":"2011: the immune hallmarks of cancer","volume":"60","author":"Cavallo","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"10.1016\/j.ejca.2013.09.016_b0170","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.2174\/138161209788453275","article-title":"Angiogenesis: complexity of tumor vasculature and microenvironment","volume":"15","author":"Furuya","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.ejca.2013.09.016_b0175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nmat3550","article-title":"Polymer multilayer tattooing for enhanced DNA vaccination","volume":"12","author":"Demuth","year":"2013","journal-title":"Nat Mater"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.016_b0180","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"issue":"12","key":"10.1016\/j.ejca.2013.09.016_b0185","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1182\/blood-2006-08-039131","article-title":"Kit is essential for PMA-inflammation-induced mast-cell accumulation in the skin","volume":"109","author":"Waskow","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2013.09.016_b0190","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/j.1582-4934.2011.01472.x","article-title":"A novel regulation of VEGF expression by HIF-1\u03b1 and STAT3 in HDM2 transfected prostate cancer cells","volume":"16","author":"Rathinavelu","year":"2012","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.016_b0195","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-Initiating cells, relieves immunosuppression and improves chemotherapeutic response","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2013.09.016_b0200","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3816\/CBC.2008.n.062","article-title":"A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338","volume":"8","author":"Chew","year":"2008","journal-title":"Clin Breast Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913008782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913008782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T04:55:56Z","timestamp":1596689756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913008782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0959804913008782"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.09.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA vaccination against membrane-bound Kit ligand: A new approach to inhibiting tumour growth and angiogenesis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2013.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}